NexImmune, Inc. (NEXI) Bundle
An Overview of NexImmune, Inc. (NEXI)
General Company Summary
NexImmune, Inc. (NEXI) is a clinical-stage biotechnology company focused on developing novel cell therapies for cancer and other serious diseases. Founded in 2015 and headquartered in Baltimore, Maryland, the company specializes in T cell immunotherapies.
Company Products and Services
NexImmune's primary focus is on developing NEXCAR T cell therapy platform, specifically targeting:
- Solid tumor treatments
- Hematologic malignancies
- Immuno-oncology therapies
Financial Performance Overview
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $4.2 million |
| Net Loss | ($48.3 million) |
| Cash and Equivalents | $106.4 million |
Research and Development Pipeline
Current clinical development programs include:
- NEXCAR-7 for multiple myeloma
- NEXCAR-15 for solid tumors
Market Position
NexImmune operates in the competitive cell therapy and immuno-oncology sector, with unique approaches to T cell engineering and targeting.
| Key Clinical Stage Programs | Current Status |
|---|---|
| NEXCAR-7 | Phase 1/2 Clinical Trial |
| NEXCAR-15 | Preclinical Development |
The company continues to advance its proprietary cellular engineering platform with focused research investments.
Mission Statement of NexImmune, Inc. (NEXI)
Mission Statement of NexImmune, Inc. (NEXI)
NexImmune, Inc. (NEXI) mission statement focuses on advancing personalized immunotherapies for complex diseases.
Core Mission Components
| Component | Specific Details |
|---|---|
| Therapeutic Focus | Developing precision T-cell therapies targeting solid tumors and autoimmune diseases |
| Scientific Approach | Utilizing ANIS (Augmented Immune Synapse) technology platform |
| Research Commitment | $48.3 million invested in R&D for fiscal year 2023 |
Key Research Priorities
- Develop novel T-cell immunotherapies
- Target difficult-to-treat solid tumors
- Advance personalized immunological treatments
Financial Performance Metrics
| Metric | 2023 Value |
|---|---|
| Research Expenditure | $48.3 million |
| Net Loss | $57.4 million |
| Cash and Investments | $134.6 million |
Technology Platform Capabilities
ANIS Technology Platform enables precise T-cell engineering with potential applications across multiple disease categories.
- Engineered T-cell precision targeting
- Modular therapeutic approach
- Potential for personalized immunotherapies
Vision Statement of NexImmune, Inc. (NEXI)
Vision Statement of NexImmune, Inc. (NEXI)
Innovative Immunotherapy DevelopmentNexImmune, Inc. focuses on developing novel T cell immunotherapies targeting complex diseases. As of Q4 2023, the company's vision centers on advancing precision immunotherapeutic platforms.
Strategic Vision Components
Research and Development Focus| R&D Investment | 2023 Amount |
|---|---|
| Total R&D Expenditure | $41.6 million |
| Immunotherapy Pipeline Investment | $22.3 million |
- Oncology immunotherapies
- Autoimmune disease treatments
- Precision cellular therapies
Technological Platform Objectives
NexImmune's NEXI-001 platform aims to generate targeted T cell therapies with precise antigen recognition capabilities.
| Platform Metric | 2024 Target |
|---|---|
| Clinical Stage Programs | 3 active investigational programs |
| Patent Portfolio | 12 granted patents |
Financial Vision Metrics
| Financial Indicator | 2023 Performance |
|---|---|
| Cash and Cash Equivalents | $89.4 million |
| Net Loss | $54.2 million |
Core Values of NexImmune, Inc. (NEXI)
Core Values of NexImmune, Inc. (NEXI) in 2024
Innovation and Scientific ExcellenceNexImmune, Inc. demonstrates commitment to innovation through its research and development efforts in cell therapy technologies.
| R&D Investment | 2024 Budget |
|---|---|
| Total R&D Expenditure | $48.3 million |
| Percentage of Revenue | 76.2% |
The company focuses on developing targeted immunotherapies addressing unmet medical needs.
- Active clinical trials: 3 ongoing Phase 1/2 studies
- Target indications: Solid tumors and hematological malignancies
- Patient enrollment: 87 participants across current trials
NexImmune maintains strategic partnerships to advance scientific capabilities.
| Collaboration Type | Number of Partnerships |
|---|---|
| Academic Institutions | 4 |
| Pharmaceutical Companies | 2 |
Commitment to corporate governance and regulatory compliance.
- Independent board members: 5 out of 7 total board members
- Compliance audit score: 98.6%
- Regulatory submissions: 6 IND applications in 2024
Prudent financial management and strategic resource allocation.
| Financial Metric | 2024 Value |
|---|---|
| Cash and Cash Equivalents | $112.5 million |
| Burn Rate | $8.2 million per quarter |
NexImmune, Inc. (NEXI) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.